Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Apellis Pharmaceuticals (NASDAQ:APLS) to a hold rating in a research note published on Saturday morning.

Other research analysts have also issued reports about the stock. Wedbush cut their target price on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Royal Bank Of Canada cut their target price on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th. Citigroup reissued a “neutral” rating and issued a $41.00 target price (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. William Blair lowered shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Mizuho raised their target price on shares of Apellis Pharmaceuticals from $20.00 to $41.00 and gave the company a “neutral” rating in a report on Thursday, April 2nd. Three equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Apellis Pharmaceuticals has an average rating of “Hold” and an average target price of $35.72.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $41.03 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.63 and a quick ratio of 3.16. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $41.14. The company has a 50 day simple moving average of $32.77 and a two-hundred day simple moving average of $26.15. The firm has a market cap of $5.25 billion, a P/E ratio of 40.23 and a beta of -0.24.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.44. Apellis Pharmaceuticals had a net margin of 12.06% and a return on equity of 39.71%. The business had revenue of $268.30 million during the quarter, compared to analyst estimates of $208.91 million. On average, equities analysts expect that Apellis Pharmaceuticals will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new stake in Apellis Pharmaceuticals in the first quarter worth $52,000. Jones Financial Companies Lllp lifted its position in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after buying an additional 1,373 shares during the last quarter. Allworth Financial LP lifted its position in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after buying an additional 857 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Apellis Pharmaceuticals during the third quarter worth $64,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.